is reading and analyzing
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$VYCO goin' M80 after new CEO announcement
$VYCO Only one MM til .025
I feel ya. I bought low, and should've sold on the news in May. Honestly, now I'm holding something that stagnates without being pumped. I don't want to sell low and cut my losses, because I believe there's potential. Eh.
$VYCO big volume after new CEO announcement
"Richard Denness is a healthcare executive with global experience who has
held senior management positions at UCB, Inc., Schwarz Pharma US,
Schering-Plough and IVAX Corporation."
http://www.reuters.com/article/2012/07/02/idUS169622+02-Jul-2012+MW20120702
$VYCO- a true rarity:
Technology Video: http://player.vimeo.com/video/39903199
-200% increase in revenues in a $20B international market
-Strong international patent suite to proprietary technology
-Legit endorsement from medical and scientific community. They have Harvard Med School Professors on the advisory board
-Technology that literally restores sight to the blind and makes inoperable brain procedures possible, 2000 medical procedures already performed
- Market gaining momentum WITHOUT promo's. 14xs the average volume -Competition is largely non-existent
-VBAS lauded in peer reviewed journals at Johns Hopkin's University, Cleveland Clinic, University of Illinois as technically superior
- Over fifteen years of clinical research, it has been shown that in approximately 70% of cases patients using NovaVision's VRT system over a three to six month period experience significant recovery in at least one functional outcome. In many cases this
recovery is enough to restore lost abilities such as reading, avoiding unseen objects while walking, or in some cases even driving a car.
Quote from Harbinger Research, which gave $VYCO it's highest investment rating:
"The Company Should Enter Hyper-growth During the Next Two to Three Years
Vycor's ViewSite is already making good inroads into the relatively small neurosurgery
market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early
2013. However, we are most excited about the long-term potential of the NovaVision
subsidiary, as its products have no real competition and address a global market that could be
up to $20B in size. Although NovaVision's products could require several years to achieve
market penetration of even 5%, this would still equate to a huge win for a company of this size.
Both NovaVision and ViewSite have strong patent protection and backing from the scientific
community, and both are FDA 510(k) cleared for sale in the United States."
The report (enough DD to choke a camel)
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
Check out the board, and thanks for reading!
$VYCO takes on new powerhouse CEO:
Mon Jul 2, 2012 2:01pm EDT
BOCA RATON, FL, Jul 02 (Marketwire) --
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) today announces that Richard
P. Denness will be joining Vycor as its new Chief Executive Officer,
replacing Ken Coviello. During this transition period, Ken will retain a
role with the company on a consultancy basis. Since the acquisitions of
NovaVision, Inc. and Sight Science Limited, Vycor has become an
international group of greater complexity with several businesses.
Richard Denness is a healthcare executive with global experience who has
held senior management positions at UCB, Inc., Schwarz Pharma US,
Schering-Plough and IVAX Corporation.
Kenneth T. Coviello, the current Chief Executive Officer of Vycor, has
played a crucial role in the development of Vycor and its VBAS product
line, which has been achieving excellent growth and progress in US and
international markets. Ken had indicated to the Board a desire to pursue
personal interests and pass the role on to a new executive to take Vycor
forward to the next level, once an appropriate successor could be found.
Adrian Liddell, Chairman of Vycor, stated: "We are delighted to welcome
Richard as the new CEO of Vycor; Richard has the operations, strategic,
and management leadership experience required to run a fast moving
healthcare company such as Vycor. We believe he is ideally equipped to
take Vycor forward into the next exciting phase of its development. At
the same time, Vycor owes a huge debt of gratitude to Ken, who has led
the company from inception and we wish him all the best with his future
plans."
http://www.reuters.com/article/2012/07/02/idUS169622+02-Jul-2012+MW20120702
$VYCO Market gaining momentum WITHOUT promo's. 14xs the average volume
-200% increase in revenues in a $20B international market
-Strong international patent suite to proprietary technology
-Technology that literally restores sight to the blind and makes inoperable brain procedures possible, 2000 medical procedures already performed
-Competition is largely non-existent
-VBAS lauded in peer reviewed journals at Johns Hopkin's University, Cleveland Clinic, University of Illinois as technically superior
$VYCO .0205 x .021 --->
-200% increase in revenues in a $20B international market
-Strong international patent suite to proprietary technology
-Legit endorsement from medical and scientific community. They have Harvard Med School Professors on the advisory board
-Technology that literally restores sight to the blind and makes inoperable brain procedures possible, 2000 medical procedures already performed
- Market gaining momentum WITHOUT promo's. 14xs the average volume -Competition is largely non-existent
-VBAS lauded in peer reviewed journals at Johns Hopkin's University, Cleveland Clinic, University of Illinois as technically superior
- Over fifteen years of clinical research, it has been shown that in approximately 70% of cases patients using NovaVision's VRT system over a three to six month period experience significant recovery in at least one functional outcome. In many cases this
recovery is enough to restore lost abilities such as reading, avoiding unseen objects while walking, or in some cases even driving a car.
$VYCO razor-thin float: The Company Should Enter Hyper-growth During the Next Two to Three Years.
Vycor's ViewSite is already making good inroads into the relatively small neurosurgery
market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early
2013. However, we are most excited about the long-term potential of the NovaVision
subsidiary, as its products have no real competition and address a global market that could be
up to $20B in size. Although NovaVision's products could require several years to achieve
market penetration of even 5%, this would still equate to a huge win for a company of this size.
Both NovaVision and ViewSite have strong patent protection and backing from the scientific
community, and both are FDA 510(k) cleared for sale in the United States.
-Harbinger Research
$VYCO groundbreaking medical technology:
ViewSite Helps Neurosurgeons Address "Inoperable" Cases and Improves Outcomes
The transparent ViewSite Brain Access System (VBAS) dramatically reduces the damage
caused by "retractors" that surgeons now use to reach sub-surface areas of the brain. It also
provides these surgeons with superior visibility during surgical procedures. The net effect of
this is improved clinical outcomes, shorter surgeries, and shorter recovery times; in some cases
this product's superior attributes have allowed brain surgeons to successfully perform surgeries
that would have otherwise been considered inoperable. The VBAS is protected by a strong
patent portfolio, and we believe its clinical superiority and cost savings will lead it to become
the de facto standard in surgical devices for neurosurgery over the next few years.
-Harbinger Research
$VYCO $1B+ Market Opportunity - First Real Treatment for Stroke-Related Vision Loss
Vycor's NovaVision helps victims of stroke and traumatic-brain injury permanently regain a
key portion of lost vision-field. This is the first treatment for what has been considered a
permanent and irreversible condition, and is backed by a strong scientific team, 15 years of
research and 20 clinical studies. It is FDA 510(k) cleared, has a strong patent portfolio, and
addresses a very large market in the United States, Europe, and around the world. Although
we believe it will take NovaVision several years to penetrate a big percentage of this market,
its multi-billion dollar size makes this product line a potential blockbuster for Vycor.
-Harbinger Research
Yep. Somebody caught the bounce.
I believe this could be an explosive week for VYCO, so much so, that all the investors will be independently wealthy. We'll have a celebration and call it "independence day", complete with explosive devices, bbq, and sunburns. <--IMO
So far there's been a few conference calls with one of the principals of the company and recent investors. It's a great opportunity to hear about the company's history and direction straight from the horse's mouth. There's also a Q&A section at the end. If you're interested, we can keep you posted on plans for the next one.
$VYCO up 10%. Super thin resistance. Check the board for loads of DD!
$VYCO up 10%, resistance is futile
$VYCO more than triple week's volume!
255 back at ya!
*picture of bruce lee kicking chuck norris*
$VYCO!!
Anyone know how much is left at bid? NITE still camping out?
Nice accumulation right out of the gate. How much is left at bid?
Excellent. More than double yesterday's volume.
I'm not trying to start a political discussion, but, I wonder if today's supreme court decision will have any bearing on the markets. If so, what will it do for a healthcare industry like VYCO?
Can we get an L2 update please and thanks?
I believe yesterday's volume was 35,000.
With what's already happened this morning, I'd like to see us get twice the volume of yesterday.
Cant argue with the steadiness, but, Friday usually rocks the boat.
Who's got two thumbs and is usually quoted as saying "the dips don't last long here"?
VYCO New brain tumor technology helps man who took two bullets to the head return to normal life:
One fragment in the right side was close to the sinus and another was in the left side where the visual cortex resides. He removed them both.
"We would not have attempted this without this technology," Sundaresan said. "It's very exciting."
VYCO New brain tumor technology helps man who took two bullets to the head return to normal life:
http://articles.nydailynews.com/2011-06-19/news/29696861_1_vada-vasquez-sundaresan-stray-bullet
Brilliant. This is the kind of real-life success story that creates a buzz.
338!
Actually, Tangerine said that in his post. 3.4m in debts.
New here. Just thought I'd see what the buzz was about. Nice to see a board with investors, pumpers, and bashers duking it out over DD :)
“GlobalWise is positioning itself for record-breaking growth for the balance of 2012 and 2013,”
Tommy likey.
Wow. We dropped .001 on 1000 shares sold? That is razor thin float.
Good story there stevo. Do you have the link?
Agreed. I heard somewhere that it takes an average of 8 months for a new product/method to be fully operational in the average US hospital. We're a lot more stringent over here. Of course, VYCO having FDA approval certainly helps to move the process along.
Greetings. I'd like to throw my 2 cents in about VYCO.
442m O/S (65% internally held)
Insanely low float (still trying to track down the exact figure)
-200% increase in revenues in a $20B international market
-Strong international patent suite to proprietary technology
-Little to no competition
-Legit endorsement from medical and scientific community. They have Harvard Med School Professors on the advisory board
-Technology that literally restores sight to the blind and makes inoperable brain procedures possible, 2000 medical procedures already performed
- Market gaining momentum WITHOUT promo's. 14xs the average volume -Competition is largely non-existent
-VBAS lauded in peer reviewed journals at Johns Hopkin's University, Cleveland Clinic, University of Illinois as technically superior
- Over fifteen years of clinical research, it has been shown that in approximately 70% of cases patients using NovaVision's VRT system over a three to six month period experience significant recovery in at least one functional outcome. In many cases this
recovery is enough to restore lost abilities such as reading, avoiding unseen objects while walking, or in some cases even driving a car.
The Company Should Enter Hyper-growth During the Next Two to Three Years
Vycor's ViewSite is already making good inroads into the relatively small neurosurgery
market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early
2013. However, we are most excited about the long-term potential of the NovaVision
subsidiary, as its products have no real competition and address a global market that could be
up to $20B in size. Although NovaVision's products could require several years to achieve
market penetration of even 5%, this would still equate to a huge win for a company of this size.
Both NovaVision and ViewSite have strong patent protection and backing from the scientific
community, and both are FDA 510(k) cleared for sale in the United States.
It's an up-front price regardless. They can tack on additional things during the surgery, but it's pretty set in stone.
-Also limiting the chance of infection by covering patient's exposed brain tissue.